

## NPCA Newsletter, Winter 2019

### Annual Report 2019

Thank you to all members of Trust teams who collected and submitted data for this year's Annual Report. **The report will be published on the 9th January 2020** and available for download on our [web-site](#).

In this report we will present results from the prospective audit for men diagnosed with, or treated for, prostate cancer between 1<sup>st</sup> April 2017 and 31<sup>st</sup> March 2018 in England and Wales.

We report on specific information relating to diagnosis, staging and treatment, as well as [core performance indicators](#), in order to compare diagnostic specialist MDTs and/or treatment centres. This is the first time we report on the use of docetaxel, brachytherapy boost (high-dose rate and low-dose rate) and radiotherapy hypofractionation.


We look forward to continuing to work with you in 2020 to ensure the success of the NPCA and ultimately to improve the quality of care and outcomes of patients nationwide.

#### The NPCA team

### NPCA Patient Survey 2020: patient reported outcomes and patient experience

Starting in January 2020, the NPCA will carry out an additional six-month period of data collection for the [NPCA Patient Survey](#) designed to determine patients' views of their experience of care and outcomes following diagnosis and treatment.

We will send a questionnaire to men with localised (non-metastatic) prostate cancer at least 18 months post-diagnosis. This includes **men diagnosed between 1<sup>st</sup> April 2018 and 30<sup>th</sup> September 2018 who subsequently underwent radical surgery or radiotherapy treatment.**



Previously, [a patient survey](#) was sent to men diagnosed between 1<sup>st</sup> April 2014 and 30<sup>th</sup> September 2016 who underwent, or who were candidates for, radical treatment. **Over 47,000 surveys were sent to men in England and Wales with an overall response rate of 73%.**

The most recent results from the NPCA Patient Survey were presented in the [NPCA Annual Report 2018](#). Individual [provider-level results](#) and a [Patient Summary](#) are available on our website.

Please find attached an [explanatory letter](#) and a [poster](#), which we hope you can display in outpatient clinics. Above and beyond this, **no further actions are required from your Trust.**

## NPCA Quality Improvement workshop

The [first national NPCA Quality Improvement workshop 'Reducing treatment-related toxicity after radical prostate cancer treatment'](#) took place in London on the 13th December. Over 65 urologists, oncologists and nurses from across England and Wales participated in the workshop. Thank you to everyone who attended and contributed to the success of this event.



Please check the NPCA website throughout 2020 for updates regarding outputs from the workshop and future quality improvement initiatives.

**The NPCA Short Report 2019 'Prostate Biopsy Technique' describing the current national practice in the use of transperineal biopsies and how the risk of complications is affected by the biopsy approach was published 13.12.19 and is available to download [here](#)**

## NPCA Minimum Dataset–CancerStats updates

The [NPCA Minimum Dataset](#) comprises COSD data items only and are part of your routine monthly submissions to the National Cancer Registration and Analysis Service (NCRAS).

To review your Trust's data completeness, please use the NCRAS CancerStats website. This is a cancer information portal designed to bring together all reporting products from the NCRAS in one easy-to-find location (N3 connection required).

<https://cancerstats.ndrs.nhs.uk>

New NPCA reports are available on CancerStats:

1. **NPCA L2 Data Completeness Reports** enable users to monitor the completeness of COSD data returns in real time .
2. **NPCA Quarterly Reports** are also provided which focus on key data items including TNM staging, Performance Status, CNS contact, PSA (Diagnosis), Prostate Biopsy Technique, Consultant Code (Surgeon), Procedure - Nerve sparing and Radical Prostatectomy Margin Status.

The success of the NPCA is reliant on the data quality (completeness) of the submissions of routine national datasets. Please go to the [COSD website](#) for further information including submission dates, how to register for the CancerStats portal and contacts for regional NCRAS Liaison Managers.

**NPCA Annual Report 2020– data submissions were due 14.10.19. Please contact your regional NCRAS Liaison Manager should you require support with your data submissions for the 2020 report.**